The data is also a big relief for AZ, which paid a hefty $1.4 billion upfront to license rights to Enhertu in a deal that could be worth up to $6.9 billion to Daiichi Sankyo if all the ADC's ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

Enhertu is a HER2-directed ADC, combining a monoclonal antibody with topoisomerase 1 inhibitor payloads. Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

Daiichi discovered the ADC and tailored it leveraging its DXd ... Daiichi Sankyo R&D global head Ken Takeshita said: “Enhertu is the first HER2 directed medicine to demonstrate an improvement ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Enhertu and Datroway are forecast to pull in $13.9bn and $5.3bn in sales in 2030, respectively, according to GlobalData’s Pharma Intelligence Center. "Daiichi Sankyo buys solid tumour ADC from ...

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.